AU Patent

AU2014253493B2 — Tetrahydro-pyrido-pyrimidine derivatives

Assigned to Novartis AG · Expires 2016-04-14 · 10y expired

What this patent protects

H.:\re\tevoven\NRPo,,I\DCC\REC\6908418_Ldocx -21/1/20 14 The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (1), -N N( wherein Y, R", R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disor…

USPTO Abstract

H.:\re\tevoven\NRPo,,I\DCC\REC\6908418_Ldocx -21/1/20 14 The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (1), -N N( wherein Y, R", R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the P13K enzymes.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014253493B2
Jurisdiction
AU
Classification
Expires
2016-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.